For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...